Abstract
Despite many advances achieved to date, heart failure (HF) remains a leading cause of morbidity and mortality. There is a widely-accepted consensus that HF and diabetes are strongly linked by at least 3 mechanisms: associated comorbidities, coronary atherosclerosis or a specific diabetic cardiomiopathy. For the last 2 mechanisms, advanced glycation end-products may contribute to trigger key processes relevant to HF by affecting cardiac function through cross-linking or receptor engagement. This review focuses on the main effects of advanced glycation end-products on cardiomyocytes and endothelial cell function. Some pharmacological approaches are also discussed.
Keywords: Advanced glycation, heart failure, glucose imbalance, diabetes, cardiomyocytes, oxidative stress
Current Vascular Pharmacology
Title: Advanced Glycation and ROS: A Link between Diabetes and Heart Failure
Volume: 6 Issue: 1
Author(s): Armando Rojas, Enrique Mercadal, Hector Figueroa and Miguel A. Morales
Affiliation:
Keywords: Advanced glycation, heart failure, glucose imbalance, diabetes, cardiomyocytes, oxidative stress
Abstract: Despite many advances achieved to date, heart failure (HF) remains a leading cause of morbidity and mortality. There is a widely-accepted consensus that HF and diabetes are strongly linked by at least 3 mechanisms: associated comorbidities, coronary atherosclerosis or a specific diabetic cardiomiopathy. For the last 2 mechanisms, advanced glycation end-products may contribute to trigger key processes relevant to HF by affecting cardiac function through cross-linking or receptor engagement. This review focuses on the main effects of advanced glycation end-products on cardiomyocytes and endothelial cell function. Some pharmacological approaches are also discussed.
Export Options
About this article
Cite this article as:
Rojas Armando, Mercadal Enrique, Figueroa Hector and Morales A. Miguel, Advanced Glycation and ROS: A Link between Diabetes and Heart Failure, Current Vascular Pharmacology 2008; 6 (1) . https://dx.doi.org/10.2174/157016108783331312
DOI https://dx.doi.org/10.2174/157016108783331312 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Diabetes on Murine Lipoproteins and Vascular Disease
Current Drug Targets Vascular Pathology from Smoking: Look at the Microcirculation!
Current Vascular Pharmacology The 21st Century Form of Vitamin E - Tocotrienol
Current Pharmaceutical Design Application of Pharmacogenomic Approaches in the Study of Drug Response in Complex Diseases
Current Pharmacogenomics Application of Immunological Techniques (from Vaccination to Final Measurements) in Determination of Pharmaceutical Residues in Environmental Samples
Current Analytical Chemistry Surgical Complications of Hyperglycaemia
Current Diabetes Reviews The VHL Tumor Suppressor: Master Regulator of HIF
Current Pharmaceutical Design Re-Discovering PDE3 Inhibitors - New Opportunities for a Long Neglected Target
Current Topics in Medicinal Chemistry Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome
Current Pharmaceutical Design A Multidisciplinary Atrial Fibrillation Clinic
Current Cardiology Reviews Atrial Fibrillation in Heart Failure: An Innocent Bystander?
Current Cardiology Reviews Specific Therapy Based on the Genotype and Cellular Mechanism in Inherited Cardiac Arrhythmias. Long QT Syndrome and Brugada Syndrome
Current Pharmaceutical Design Beta-2 Agonists in Asthma: Medicine or Murderer?
Current Respiratory Medicine Reviews Notch Inhibitors as a New Tool in the War on Cancer: A Pathway to Watch
Current Pharmaceutical Biotechnology Antipsychotic-Induced Electrocardiographic Changes: A Comparative Study Between Olanzapine and Risperidone
Current Psychopharmacology Coronary Artery Disease in Patients with Chronic Kidney Disease: A Clinical Update
Current Cardiology Reviews Stem Cell Implantation for Myocardial Disorders
Current Drug Delivery Targeting the PI3K/Akt/mTOR Axis by Apigenin for Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Cisplatin Is a DNA-Damaging Antitumour Compound Triggering Multifactorial Biochemical Responses in Cancer Cells: Importance of Apoptotic Pathways
Current Medicinal Chemistry - Anti-Cancer Agents <i>In silico</i>-based Approach to Investigate the Ability of PEGylated Rapamycin to Inhibit Galectin-3
Current Drug Discovery Technologies